BRADLEY PHARMACEUTICALS INC
Previous company name
Name change date
Bradley Pharmaceuticals Inc. is a specialty pharmaceutical company that provides therapies to niche physician specialties in the United States and 38 international markets. The company manufactures and markets brand name prescription and over-the-counter drugs and health-related products, including dermatological and respiratory therapy. Founded in January 1985, the US-based company has its corporate headquarters located in Fairfield, New Jersey.
Bradley Pharmaceuticals Inc. has two subsidiaries: Doak Dermatologics (delivers dermatology and podiatry therapies) and Kenwood Therapeutics (provides gastroenterology, OB/GYN and internal medicine brands). The Doak Dermatologics subsidiary of Bradley Pharmaceuticals has an 80-year history of providing skincare therapies to specialty physician audiences. Serving both the dermatology and podiatry communities, Doak brands provide symptomatic relief for a wide range of patients suffering from uncomfortable and often chronic skin and nail conditions, including acne, rosacea, actinic keratosis, psoriasis, seborrheic dermatitis and pruritic conditions such as eczema and dermatitis. The Kenwood Therapeutics division of Bradley Pharmaceuticals has a 60-year history of providing gastroenterology, OB/GYN and internal medicine therapies to niche physician audiences. Kenwood brands help promote a better quality of life for patients suffering from chronic conditions including GI hypermotility, hemorrhoids and poor intestinal function.
Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, develops and markets prescription and over-the-counter products in niche therapeutic markets, including dermatology, podiatry, gastroenterology and women’s health. The Company has two primary business segments, its Doak Dermatologics subsidiary (which includes the products acquired from Bioglan Pharmaceuticals), specializing in therapies for dermatology and podiatry, and its Kenwood Therapeutics division, providing gastroenterology, women’s health, respiratory and other internal medicine brands. To a lesser extent, Kenwood Therapeutics also markets nutritional supplements and respiratory products. During the year ended December 31, 2006, the Company launched its A. Aarons subsidiary, which markets authorized generic versions of Doak’s and Kenwood’s products. In February 2008, the Company was acquired by Nycomed US Inc., a unit of Swiss pharmaceutical company, Nycomed.
Description and history
Bradley Pharmaceuticals, Inc., incorporated in January 1985, is a specialty pharmaceutical company that acquires, develops and markets prescription and over-the-counter products in niche therapeutic markets, including dermatology, podiatry, gastroenterology and women’s health. The Company has two primary business segments, its Doak Dermatologics subsidiary (which includes the products acquired from Bioglan Pharmaceuticals), specializing in therapies for dermatology and podiatry, and its Kenwood Therapeutics division, providing gastroenterology, women’s health, respiratory and other internal medicine brands. To a lesser extent, Kenwood Therapeutics also markets nutritional supplements and respiratory products. During the year ended December 31, 2006, the Company launched its A. Aarons subsidiary, which markets authorized generic versions of Doak’s and Kenwood’s products. In February 2008, the Company was acquired by Nycomed US Inc., a unit of Swiss pharmaceutical company, Nycomed.
ADOXA, doxycycline monohydrate, is a member of the tetracycline family of antibiotics and is available in 150-milligram, 100-milligram, 75-milligram and 50-milligram tablets. ADOXA is available in bottles of tablets and as ADOXA Pak, a convenient package that may enhance patient compliance and encourage physician prescribing. The tetracycline family of antibiotics is useful adjunctive therapy for the treatment of severe acne. These medications work by suppressing the common bacteria, P. acnes (the causative agent for acne), on the skin. They are often used in conjunction with topical therapies as part of an overall acne treatment regimen. ADOXA is one of several branded tetracycline products for acne treatment.
KEROL and KERALAC are prescription urea-based topical moisturizing therapies with keratolytic properties (helps to remove the surface layer of dead cells). KEROL is available as a urea-medicated cloth in its own packaging. The Company launched KEROL, in 2006, as a line extension to KERALAC. KERALAC is available in five formulations: a lotion, cream, nail gel, ointment and a Nailstik. KERALAC LOTION is marketed for mild to moderate dry skin, KERALAC CREAM is marketed for moderate to severe dry skin and KERALAC GEL is marketed for site-specific dry skin, nail debridement and as a nail softener. KERALAC NAILSTIK is an application to treat diseased and damaged nails. KERALAC OINTMENT is a site-specific treatment for dry skin relief. The Company developed KERALAC as an enhancement to its CARMOL40 products
SOLARAZE Gel is a dermatological product containing the non-steroidal, anti- inflammatory diclofenac sodium in a 3% topical formulation. SOLARAZE Gel is used to treat actinic keratosis. SOLARAZE Gel is also a topical treatment for actinic keratosis that is approved for use on other parts of the body besides the face and scalp. ZODERM CLEANSER, ZODERM CREAM, ZODERM GEL and ZODERM REDI-PADS are internally developed benzoyl peroxide topical prescription products that help treat acne. The active ingredient in all ZODERM products is benzoyl peroxide, which has antibacterial properties that are effective in treating acne.
LIDAMANTLE and LIDAMANTLE HC, available in cream and lotion formulations, are prescription products with a topical anesthetic (lidocaine) that help relieve pain, soreness, itching and irritation caused by insect bites, eczema and other skin conditions. LIDAMANTLE and LIDAMANTLE HC are formulated in a special base that mimics the pH of healthy skin, thus providing an environment that facilitates healing, protects against infections and alleviates irritation. LIDAMANTLE HC also contains hydrocortisone, which helps to reduce inflammation.
ROSULA AQUEOUS CLEANSER, ROSULA AQUEOUS GEL and ROSULA NS PADS are internally developed topical prescription products that treat skin conditions, including acne and rosacea. The active ingredients in ROSULA AQUEOUS GEL and ROSULA AQUEOUS CLEANSER, sodium sulfacetamide and sulfur, have antibacterial properties that are effective against acne and reduce the redness (erythema) and lesions associated with rosacea. The active ingredient in ROSULA NS PADS, sodium sulfacetamide, also acts as an antibacterial that is effective for acne and rosacea.
PAMINE and PAMINE FORTE are prescription lactose-free, antispasmodic oral therapies that are indicated for the adjunctive therapy of peptic ulcer. PAMINE FORTE contains twice the amount of methscopolamine bromide, the active ingredient of PAMINE, and may be taken less frequently than PAMINE. Because both PAMINE and PAMINE FORTE have limited ability to cross the blood-brain barrier (BBB), they cause fewer side effects, such as dizziness and blurred vision.
ANAMANTLE HC is a prescription cream containing a topical anesthetic (lidocaine) and hydrocortisone (an anti-inflammatory), which treats hemorrhoids and anal fissures. Because ANAMANTLE HC is formulated in a pH-balanced base, it can encourage a pH that facilitates healing, reduces swelling and soothes irritation. ANAMANTLE HC cream is packaged as a kit containing 20 single-use units, each containing a single-use tube and applicator, as well as a soothing cleansing wipe. ANAMANTLE HC FORTE delivers twice the anti-inflammatory medication of the original ANAMANTLE HC and contains mucoadhesive properties that are designed to promote better adhesion to affected areas. During 2006, the Company launched ANAMANTLE HC GEL, a topical treatment for hemorrhoids and anal fissures containing 2.5% hydrocortisone and 3% lidocaine.
FLORA-Q is an over-the-counter nutritional supplement blend of bacterial strains designed to promote the proper balance of natural healthful bacteria in the intestines, often referred to as probiotics. FLORA-Q contains four strains of probiotic bacteria in a novel delivery system that ensures safe passage of the probiotic strains through the stomach and high-potency delivery to the intestinal tract, where its beneficial effect is realized. In addition, FLORA-Q requires no refrigeration and is available in a capsule form.
VEREGEN is a topical ointment indicated for the treatment of external genital and perianal warts. The active ingredient in VEREGEN is a defined mixture of catechins extracted from green tea, a novel active ingredient, that has been proven effective for the treatment of external genital and perianal warts caused by certain strains of HPV. Existing treatment for external genital or perianal warts primarily consists of cryosurgery and the topical therapy Aldara. ELESTRIN is an estradiol transdermal gel indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The Company’s A. Aarons subsidiary, which commenced operations during 2006, sells generic versions of our ZODERM, ANAMANTLE HC, PAMINE, PAMINE FORTE, CARMOL 40 and KERALAC brands.
Bradley Pharmaceuticals, Inc. competes with Axcan Pharma, Barrier Therapeutics CollaGenex Pharmaceuticals, Graceway Pharmaceuticals, King Pharmaceuticals, Medicis, Salix Pharmaceuticals, Sciele Pharma, Stiefel Laboratories, Valeant Pharmaceuticals and Wyeth Pharmaceuticals.
Engaged in the manufacture and marketing of brand name prescription and over-the-counter drugs and health-related products, including dermatological and respiratory therapy
GRANT THORNTON LLP
US SIC Code
383, Route 46 West
City province or state postal code
07004, FAIRFIELD, NJ
Phone: +1 973 882 1505
Fax: +1 973 575 5366
Country address: UNITED STATES OF AMERICA
Website url: www.bradpharm.com